ALGS — Aligos Therapeutics Share News
0.000.00%
Last trade - 00:00- $29.85m
- -$0.47m
- $2.19m
Brief: Aligos Therapeutics Announces Award Of An $8.5 Million Niaid Contract To Advance Development Of Pan-Coronavirus Protease Inhibitor, Alg-097558
U.S. STOCKS ON THE MOVE-Boston Scientific, Rockwell Medical, Visa
U.S. STOCKS ON THE MOVE-Fox Corp, Cisco Systems, Darden Restaurants
U.S. STOCKS ON THE MOVE-Greenbrier, Aligos
Aligos rises as FDA clears application to begin trials for NASH drug
Brief: Aligos Therapeutics Inc Announces IND Clearance For Nash Lead, Alg-055009
Brief: Aligos Therapeutics Received A Written Notice From Nasdaq Notifying Co Was Not In Compliance With Minimum Bid Price Requirement
Aligos Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Aligos Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Aligos Therapeutics Presents Data From Liver Disease Programs
U.S. STOCKS ON THE MOVE-Verizon Communications, Home Depot, Catalent
U.S. STOCKS ON THE MOVE-Oramed, Fisker, Blue Bird
U.S. STOCKS ON THE MOVE-Sarepta Therapeutics, C3.ai, Tapestry
U.S. STOCKS ON THE MOVE-NeoGames, SandRidge Energy, Shake Shack
Aligos Therapeutics soars on collaboration deal for liver disease treatment
Brief: Aligos Therapeutics Announces Research Collaboration And Development Agreement With Xiamen Amoytop Biotech Co. Ltd. For Use Of Aligos’ Oligonucleotide Platform For The Treatment Of Liver Diseases
Aligos Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Aligos Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Aligos Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview